Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines

American Journal of Gastroenterology

Volumn 105, Issue 9, 2010, Pages 2003-2008

  Teruel, Carlos ^a   Román, Antonio López San ^a   Bermejo, Fernando ^b   Taxonera, Carlos ^d   Pérez Calle, José Lázaro ^d   Gisbert, Javier P ^e   Martín Arranz, María ^f   Ponferrada, Ángel ^g   Van Domselaar, Manuel ^a   Algaba, Alicia ^b   Estellés, Jess ^c   López Serrano, Pilar ^d   Linares, Pablo M ^e   Muriel, Alfonso ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; SALAZOSULFAPYRIDINE; STEROID; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; CROHN DISEASE; ECTOPIC PREGNANCY; ENTERITIS; FATHER; FEMALE; FETUS; FETUS DEATH; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LOW BIRTH WEIGHT; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREGNANCY; PREGNANCY COMPLICATION; PREGNANT WOMAN; PREMATURITY; PRIORITY JOURNAL; PURINE METABOLISM; SPAIN; SPONTANEOUS ABORTION; TREATMENT OUTCOME; CHEMICALLY INDUCED; CLINICAL TRIAL; INFLAMMATORY BOWEL DISEASES; MULTICENTER STUDY; PREGNANCY OUTCOME; RISK;

6-MERCAPTOPURINE; AZATHIOPRINE; FATHERS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; SPAIN; TREATMENT OUTCOME;

EID: 77956341830     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.138     Document Type: Article

References (37)

1. Travis SPL, Stange EF, L é mann M et al. European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 (Suppl 1): i16-35
2. Pearson DC, May GR, Fick GH et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-142
3. Alstead EM. Inflammatory bowel disease in pregnancy. Postgrad Med J 2002; 78: 23-26
4. Caprilli R, Gassull MA, Escher JC et al. European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006; 55: 36-58
5. Alstead EM, Ritchie JK, Lennard-Jones JE et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990; 99: 443-446
6. Francella A, Dayan A, Rubin P et al. 6-Mercaptopurine is a safe therapy for child bearing patients with inflammatory bowel disease [abstract]. A case controlled study. Gastroenterology 1996; 110 (Suppl): 909
7. Tennenbaum R, Marteau P, Elefant E et al. Pregnancy outcome in inflammatory bowel diseases. Gastroenterol Clin Biol 1999; 23: 464-469
8. Moskovitz DN, Bodian C, Chapman ML et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004; 99: 656-661
9. Nø rgård B, Pedersen L, Fonager K et al. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther 2003; 17: 827-834
10. Nø rgård B, Pedersen L, Christensen LA et al. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102: 1406-1413
11. Rajapakse RO, Korelitz BI, Zlatanic J et al. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 2000; 95: 684-688
12. Ben-Neriah Z, Ackerman Z. WAGR syndrome in a baby: the result of 6-MP treatment in a father affected by Crohn's disease? Am J Gastroenterol 2001; 96: 251
13. Nø rgård B, Pedersen L, Jacobsen J et al. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 2004; 19: 679-685
14. Ligumsky M, Badaan S, Lewis H et al. Effects of 6-mercaptopurine treatment on sperm production and reproductive performance: a study in male mice. Scand J Gastroenterol 2005; 40: 444-449
15. Francella A, Dyan A, Bodian C et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9-17
16. Dejaco C, Meittermaier C, Reinisch W et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 2001; 121: 1048-1053
17. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-130
18. Donner A, Klar N. Design and Analysis of Cluster Randomization Trials in Health Research. Arnold: London, 2000
19. Tuchmann-Duplessie H, Mercier-Parot L. Production of limb malformations in rabbits by the administration of azathioprine and 6-mercaptopurine. C R Soc Biol Paris 1966; 160: 501-507
20. Mercier-Parot L, Tuchmann-Duplessie H. Limb abnormalities secondary to 6-mercaptopurine in three species: rabbit, rat and mouse. C R Soc Biol Paris 1967; 161: 762-768
21. Brown JH, Maxwell AP, McGeown MG. Outcome of pregnancy following renal transplantation. Ir J Med Sci 1991; 160: 255-256
22. Bar J, Stahl B, Hod M et al. Is immunosuppression therapy in renal allograft recipients teratogenic? A single-center experience. Am J Med Genet A 2003; 116A: 31-36
23. EBPG Expert Group on Renal Transplantation. European guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant 2002; 17 (Suppl 4): 50-55
24. Golby M. Fertility after renal transplantation. Transplantation 1970; 10: 201-207
25. Penn I, Makowski E, Droegemueller W et al. Parenthood in renal homograft recipients. JAMA 1971; 216: 1755-1761
26. Levi AJ, Fisher AM, Hughes L et al. Male infertility due to sulphasalazine. Lancet 1979; 2: 276-278
27. Riley SA, Lecarpentier J, Mani V et al. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalamine substitution. Gut 1987; 28: 1008-1012
28. Wilcox AJ, Weinberg CR, O ' Connor JF et al. Incidence of early loss of pregnancy. N Engl J Med 1988; 319: 189-194
29. Martin JA, Hamilton BE, Sutton PD et al. Centers for Disease Control and Prevention National Center for Health Statistics National Vital Statistics System. Births: final data for 2005. Natl Vital Stat Rep 2007; 56: 1-103
30. Alonso V, Fuster V, Luna F. La evoluci ó n del bajo peso al nacer en Espa ñ a (1981-2002) y su relaci ó n con las caracter í sticas de la reproducci ó n. Antropo 2005; 10: 51-60
31. Centers for Disease Control and Prevention. Congenital Malformations Surveillance Report, January 1982-December 1985. US Department of Health and Human Services: Atlanta, GA, 1988
32. Lie RT, Wilcox AJ, Skjaerven R. A population-based study of the risk of recurrence of birth defects. N Engl J Med 1994; 331: 1-4
33. Thompson M, McInnes R, Willard H. Genetics in Medicine, 4Thedn WB Saunders: Philadelphia, PA, 1996
34. Templeton A. Infertility-epidemiology, aetiology and effective management. Health Bull (Edinb) 1995; 53: 294-298
35. Buka SL, Goldstein JM, Spartos E et al. The retrospective measurement of prenatal and perinatal events: accuracy of maternal recall. Schizophr Res 2004; 71: 417-426
36. Sou SC, Chen WJ, Hsieh WS et al. Severe obstetric complications and birth characteristics in preterm or term delivery were accurately recalled by mothers. J Clin Epidemiol 2006; 59: 429-435
37. Rice F, Lewis A, Harold G et al. Agreement between maternal report and antenatal records for a range of pre and peri-natal factors: the influence of maternal and child characteristics. Early Hum Dev 2007; 83: 497-504.